PDCD1 and Hypercalcemia: In PD-1/PD-L1 blockade-related irAEs, rare observed endocrinopathies include primary adrenal insufficiency, insulin-dependent diabetes mellitus (type I), hypercalcemia, and hypoparathyroidism (Wills et al., 2018).